Country: Canada
Language: English
Source: Health Canada
PANTOPRAZOLE (PANTOPRAZOLE SODIUM)
PHARMASCIENCE INC
A02BC02
PANTOPRAZOLE
20MG
TABLET (DELAYED-RELEASE)
PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20MG
ORAL
100
Prescription
PROTON-PUMP INHIBITORS
Active ingredient group (AIG) number: 0133229002; AHFS:
APPROVED
2008-06-03
_pms-PANTOPRAZOLE Product Monograph _ _Page 1 of 50_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-PANTOPRAZOLE Pantoprazole Sodium Delayed-Release Tablets Delayed-Release Tablets, 20 mg and 40 mg pantoprazole (as pantoprazole sodium), Oral House Standard (20 mg) & USP (40 mg) Proton Pump Inhibitor PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control Number: 265478 Date of Initial Authorization: FEB 7, 2007 Date of Revision: DEC 6, 2022 _pms-PANTOPRAZOLE Product Monograph _ _Page 2 of 50_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism 03/2021 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ......................................................................................................................4 1.1 Pediatrics (<18 years of age) ....................................................................................4 1.2 Geriatrics.................................................................................................................4 2 CONTRAINDICATIONS .........................................................................................................4 4 DOSAGE AND ADMINISTRATION ........................................................................................5 4.1 Dosing Considerations .............................................................................................5 4.2 Recommended Dose and Dosage Adjustment...........................................................5 4.4 Administration................................ Read the complete document